Literature DB >> 2029356

Clinical features and management of adverse effects of quinolone antibacterials.

J H Paton1, D S Reeves.   

Abstract

The quinolone antibacterials are proving very useful in the management of infection, notably for the treatment of Gram-negative bacteria. With the increasing use of these drugs, adverse effects are being recognised more often and careful documentation is still required. In general, the quinolones are of low toxicity. Gastrointestinal adverse effects are the most common, and are usually mild; indeed, all adverse events are generally mild and resolve on withdrawal of the offending drug. Certain precautions and contraindications are apparent. Because drug-induced arthropathies occur in juvenile animals, quinolones should not be administered to pregnant or lactating women or to growing children, unless the clinical benefit outweighs the risk. Caution should also be observed in patients with previous epilepsy or severe cerebral arteriosclerosis. Neurological effects may require the use of appropriate neuro- and psychoactive drugs, as well as the withdrawal of the precipitating agent. Hypersensitivity reactions to a fluoroquinolone may require the use of antihistamines, and in some cases topical or systemic steroids, and may well preclude future use of a fluoroquinolone. Dose adjustments may be necessary in patients with reduced renal function, when the measurement of serum concentrations may be desirable. Interstitial nephritis, haematuria and acute renal failure are rare effects of quinolone therapy which will require appropriate management including withdrawal of the precipitating drug. Interactions with theophylline and warfarin are of clinical significance, and may require plasma concentration monitoring and adjustment of dosage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029356     DOI: 10.2165/00002018-199106010-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  145 in total

Review 1.  Post-marketing surveillance of the quinolones: a view from Great Britain.

Authors:  P G Davey
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

2.  The adverse effects of fluoroquinolones.

Authors:  C R Smith
Journal:  J Antimicrob Chemother       Date:  1987-06       Impact factor: 5.790

3.  Childhood complications of nalidixic acid.

Authors:  E E Anderson; B Anderson; B S Nashold
Journal:  JAMA       Date:  1971-05-10       Impact factor: 56.272

4.  Convulsions and hyperglycaemia associated with nalidixic acid.

Authors:  A G Fraser; A D Harrower
Journal:  Br Med J       Date:  1977-12-10

5.  Case report of renal failure during norfloxacin therapy.

Authors:  J Boelaert; P P de Jaegere; R Daneels; M Schurgers; B Gordts; H W van Landuyt
Journal:  Clin Nephrol       Date:  1986-05       Impact factor: 0.975

6.  Pseudoglycosuria and ciprofloxacin.

Authors:  L Drysdale; L Gilbert; A Thomson; J McDevitt; P J Scott; J D Fulton
Journal:  Lancet       Date:  1988-10-22       Impact factor: 79.321

7.  DNA breakdown by the 4-quinolones and its significance.

Authors:  C S Lewin; J T Smith
Journal:  J Med Microbiol       Date:  1990-01       Impact factor: 2.472

Review 8.  Interaction between the fluoroquinolones and the bronchodilator theophylline.

Authors:  W J Wijnands; T B Vree
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

9.  Crystalluria and ciprofloxacin, influence of urinary pH and hydration.

Authors:  S B Thorsteinsson; T Bergan; S Oddsdottir; R Rohwedder; R Holm
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

10.  Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids.

Authors:  E M Sellers; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1970 Jul-Aug       Impact factor: 6.875

View more
  9 in total

1.  In vivo and in vitro toxicodynamic analyses of new quinolone-and nonsteroidal anti-inflammatory drug-induced effects on the central nervous system.

Authors:  H Kita; H Matsuo; H Takanaga; J Kawakami; K Yamamoto; T Iga; M Naito; T Tsuruo; A Asanuma; K Yanagisawa; Y Sawada
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

3.  Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in mice.

Authors:  H Matsuo; M Ryu; A Nagata; T Uchida; J I Kawakami; K Yamamoto; T Iga; Y Sawada
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

Review 4.  Safety and tolerability of fluoroquinolones.

Authors:  S R Norrby; P S Lietman
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Safety of fluoroquinolones: An update.

Authors:  L Mandell; G Tillotson
Journal:  Can J Infect Dis       Date:  2002-01

6.  A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once daily.

Authors:  H Bassaris; E Akalin; S Calangu; R Kitzes; J Kosmidis; M Milicevic; H Noack; R Raz; E Salewski; M Sukalo
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

7.  Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine.

Authors:  G Mahr; F Sörgel; G R Granneman; M Kinzig; P Muth; K Patterson; U Fuhr; P Nickel; U Stephan
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

Review 8.  Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data.

Authors:  J Kawakami; K Yamamoto; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1994-06

9.  Preparation of Thermosensitive Gel for Controlled Release of Levofloxacin and Their Application in the Treatment of Multidrug-Resistant Bacteria.

Authors:  Danilo Antonini Alves; Daisy Machado; Adriana Melo; Rafaella Fabiana Carneiro Pereira; Patrícia Severino; Luciana Maria de Hollanda; Daniele Ribeiro Araújo; Marcelo Lancellotti
Journal:  Biomed Res Int       Date:  2016-09-05       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.